Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

<p>-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- -Clinical improvement consistently seen across key measures at week 12, mMCS response of 45.7% and endoscopic improvement of 25.7%- -MORF-057 well tolerated with no safety signals observed- -PK/PD confirm results seen in healthy volunteer studies, with median RO >99% […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/morphic-to-present-positive-emerald-1-phase-2a-data-for-morf-057-in-patients-with-moderate-to-severe-ulcerative-colitis-in-abstract-for-uegw-2023/">Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>